Stock under Rs 100: This micro-cap agrochemical company receives orders worth Rs 168.29 lakh!
The shares of the company have a PE of 13.4x, an ROE of 24 per cent and a ROCE of 18.6 per cent.
Aristo Bio-Tech & Lifescience Ltd is an agrochemical company. They are mainly engaged in the manufacturing, formulation, supplying, packaging, and job work services of various pesticides.
The company informed the exchange (NSE - SM: ARISTO) that it had received 3 orders worth Rs 168.29 lakh. Details below:
Order No -1: The company received an order worth Rs 1,00,40,000 from Heranba Industries Limited. The order includes the supply of some agrochemicals on freight- paid basis and will be executed within 7 days from LOI (August 18, 2023).
Order No -2: The company received an order worth Rs 55,84,000 from Arihant Organics. The order includes the supply of some agrochemicals on a freight- F.O.R basis and will be executed within 7 days from LOI (August 19, 2023).
Order No -3: The company received an order worth Rs 12,05,000 from Raccolto Agritech India Private Limited. The order includes the supply of some agrochemicals on a freight- F.O.R basis and will be executed within 7 days from LOI (August 19, 2023).
On Friday, shares of Aristo Bio-Tech & Lifescience plunged 1.89 per cent to Rs 70 per share with an intraday high of Rs 72.05 and an intraday low of Rs 67.60. The stock gave 18.70 per cent returns to its investors in just 1 month.
Want more insightful stories along with recommendations?
Get a 3-month subscription to experience the power of our flagship DSIJ Magazine (online edition) for just Rs 800/- Click here to subscribe now
The stock of the company was listed on NSE as an SME company with a lot size of Rs 1,600 equity shares on February 03, 2023. The company has a market cap of Rs 47.6 crore. The net sales increased by 3.15 per cent to Rs 218 crore and net profit skyrocketed 300 per cent to Rs 4 crore in FY23 over FY22. The shares of the company have a PE of 13.4x, an ROE of 24 per cent and a ROCE of 18.6 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.